Your AI-Trained Oncology Knowledge Connection!

Potential Role of Magrolimab in the Treatment of Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) : Episode 10

Potential Shift in the Treatment Paradigm of Higher-Risk MDS with Magrolimab

October 27, 2022

By Hetty E. Carraway, MD
Eytan M. Stein, MD

Video

Dr Hetty Carraway muses on whether magrolimab plus azacitadine will be used as a standard treatment for higher-risk MDS in the future.

EP: 1.An Overview of Myelodysplastic Syndrome (MDS)

EP: 2.The Progression of Myelodysplastic Syndrome to Acute Myeloid Leukemia (AML)

EP: 3.Risk Stratification for Patients with Myelodysplastic Syndrome

EP: 4.Treatment Goals for Patients with Myelodysplastic Syndrome

EP: 5.Currently Available Treatment Options for Patients with Higher-Risk Myelodysplastic Syndrome

EP: 6.Factors for Consideration when Choosing an Appropriate Treatment for Higher-Risk Myelodysplastic Syndrome

EP: 7.The Role of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome

EP: 8.The Role of Hypomethylating Agents (HMAs) in Higher-Risk Myelodysplastic Syndrome Treatment

EP: 9.Magrolimab plus Azacitidine for Myelodysplastic Syndrome

Now Viewing

EP: 10.Potential Shift in the Treatment Paradigm of Higher-Risk MDS with Magrolimab

EP: 11.Treating Patients with Myelodysplastic Syndrome and IDH or TP53 Mutations

EP: 12.Unmet Needs for Patients with Higher-Risk Myelodysplastic Syndrome

EP: 13.ENHANCE-2 Trial of Magrolimab plus Azacitidine in AML

EP: 14.ENHANCE-3 Trial of Magrolimab in Combination with Venetoclax and Azacitidine in AML

Stay up to date on practice-changing data in community practice.

Subscribe Now!

Related Content

FDA Reviews All-Oral Decitabine/Cedazuridine/Venetoclax Combo in AML

Jordyn Sava

July 11th 2025

Article

The FDA reviews an all-oral treatment for newly diagnosed AML, combining decitabine, cedazuridine, and venetoclax, showing promising trial results.

$Revumenib Gains FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML$

Revumenib Gains FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML

Sabrina Serani

June 25th 2025

Article

$FDA Clears IND for Phase 1 Study of Lonitoclax in Relapsed/Refractory AML$

FDA Clears IND for Phase 1 Study of Lonitoclax in Relapsed/Refractory AML

Jordyn Sava

June 23rd 2025

Article

FDA clears lonitoclax for a phase 1 trial in relapsed/refractory AML, promising improved safety and efficacy over existing therapies.

FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML

Jordyn Sava

June 19th 2025

Article

SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited treatment options.

$NXC-201 CAR T-Cell Therapy Shows Promise in Relapsed/Refractory AL Amyloidosis$

NXC-201 CAR T-Cell Therapy Shows Promise in Relapsed/Refractory AL Amyloidosis

Caroline Seymour

June 4th 2025

Article

$Ziftomenib Monotherapy Shows Promise in Relapsed/Refractory NPM1-Mutant AML$

Ziftomenib Monotherapy Shows Promise in Relapsed/Refractory NPM1-Mutant AML

Ashling Wahner

June 4th 2025

Article

Related Content

FDA Reviews All-Oral Decitabine/Cedazuridine/Venetoclax Combo in AML

Jordyn Sava

July 11th 2025

Article

The FDA reviews an all-oral treatment for newly diagnosed AML, combining decitabine, cedazuridine, and venetoclax, showing promising trial results.

$Revumenib Gains FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML$

Revumenib Gains FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML

Sabrina Serani

June 25th 2025

Article

$FDA Clears IND for Phase 1 Study of Lonitoclax in Relapsed/Refractory AML$

FDA Clears IND for Phase 1 Study of Lonitoclax in Relapsed/Refractory AML

Jordyn Sava

June 23rd 2025

Article

FDA clears lonitoclax for a phase 1 trial in relapsed/refractory AML, promising improved safety and efficacy over existing therapies.

FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML

Jordyn Sava

June 19th 2025

Article

SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited treatment options.

$NXC-201 CAR T-Cell Therapy Shows Promise in Relapsed/Refractory AL Amyloidosis$

NXC-201 CAR T-Cell Therapy Shows Promise in Relapsed/Refractory AL Amyloidosis

Caroline Seymour

June 4th 2025

Article

$Ziftomenib Monotherapy Shows Promise in Relapsed/Refractory NPM1-Mutant AML$

Ziftomenib Monotherapy Shows Promise in Relapsed/Refractory NPM1-Mutant AML

Do Not Sell My Information

Privacy

Terms & Conditions

Editorial Board

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Potential Shift in the Treatment Paradigm of Higher-Risk MDS with Magrolimab

EP: 1.An Overview of Myelodysplastic Syndrome (MDS)

EP: 2.The Progression of Myelodysplastic Syndrome to Acute Myeloid Leukemia (AML)

EP: 3.Risk Stratification for Patients with Myelodysplastic Syndrome

EP: 4.Treatment Goals for Patients with Myelodysplastic Syndrome

EP: 5.Currently Available Treatment Options for Patients with Higher-Risk Myelodysplastic Syndrome

EP: 6.Factors for Consideration when Choosing an Appropriate Treatment for Higher-Risk Myelodysplastic Syndrome

EP: 7.The Role of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome

EP: 8.The Role of Hypomethylating Agents (HMAs) in Higher-Risk Myelodysplastic Syndrome Treatment

EP: 9.Magrolimab plus Azacitidine for Myelodysplastic Syndrome

EP: 10.Potential Shift in the Treatment Paradigm of Higher-Risk MDS with Magrolimab

EP: 11.Treating Patients with Myelodysplastic Syndrome and IDH or TP53 Mutations

EP: 12.Unmet Needs for Patients with Higher-Risk Myelodysplastic Syndrome

EP: 13.ENHANCE-2 Trial of Magrolimab plus Azacitidine in AML

EP: 14.ENHANCE-3 Trial of Magrolimab in Combination with Venetoclax and Azacitidine in AML

Newsletter